Otsuki determined that Oxy, which is a vasodilator, is a sensitizer of xCT inhibitors, and that its GSH depletion-mediated sensitivity is beneficial to tumour ROS treatment (OTSUKI et al., 2020). The gene discussed is SLC7A11; the disease is neoplasm.